Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases.

It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

The company's development pipeline also comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).

Tourmaline Bio, Inc. was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022.

Tourmaline Bio, Inc. was incorporated in 2002 and is based in New York, New York.